Atlas Trials

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Clinical trial NCT04814108 · COMPLETED

Trial details

NCT number
NCT04814108
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Uterine Serous Carcinoma
Start date
2021-07-28
Primary completion
2025-10-22
Enrollment
92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.